Advertisement

Topics

SeaGen Ends One Leukemia Drug Trial, Stops Enrolling Three Others

09:25 EDT 19 Jun 2017 | Xconomy

Seattle Genetics is ending a Phase 3 clinical trial of its leukemia drug after a review showed more deaths in patients treated with the drug compared to the control group, the company announced this morning. Bothell, WA-based Seattle Genetics (NASDAQ: SGEN) says the decision to end the trial follows a discussion with the independent data […]

Original Article: SeaGen Ends One Leukemia Drug Trial, Stops Enrolling Three Others

NEXT ARTICLE

More From BioPortfolio on "SeaGen Ends One Leukemia Drug Trial, Stops Enrolling Three Others"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...